PHP Biotech Announces Dual Role as Featured Speaker and Sponsor at Upcoming Oncology Summit

September 11, 2026 -

PHP Biotech, a US-based biotechnology company specializing in nanobody and translational biotechnology, will participate in the upcoming Oncology Summit as both a featured speaker and an event sponsor. The dual role places the company among the presenting and supporting organizations at a gathering focused on advances in cancer research and therapeutic development.

As a featured speaker, PHP Biotech will share perspectives on nanobody-based approaches to oncology, an area that has drawn growing attention within the research community. As a sponsor, the company will contribute to the programming and infrastructure that bring together scientists, clinicians, and industry representatives during the event. The company intends for both roles to reflect its ongoing engagement with the wider oncology field.

The Summit brings together researchers and healthcare professionals to discuss developments in the treatment of aggressive cancers, including triple-negative breast cancer (TNBC). PHP Biotech works in this space through the development of therapeutic nanobodies designed to target cancer cells. Its lead candidate, PHP53-nb, is a humanized nanobody designed to enter cancer cells and reactivate the p53 protein, a key regulator associated with several aggressive cancers.

Robert Gahagen, Chief Executive Officer of PHP Biotech, said the company views the Summit as an opportunity to contribute to scientific dialogue while connecting with peers across the field. "Participation as both a speaker and a sponsor allows the company to engage with the oncology community on two fronts," Gahagen said. "Sharing research perspectives and supporting the event itself both serve the broader goal of advancing understanding of nanobody science."

Gahagen added that the format of the Summit lends itself to collaboration. "Events of this kind create space for researchers and clinicians to exchange ideas that individual organizations cannot generate alone," he said. "PHP Biotech considers that kind of exchange central to progress in translational biotechnology."

PHP Biotech is developing a dedicated event page to house details related to its Summit participation, including session information and its role as a sponsor. The page will serve as a central reference point for those seeking additional details about the company's involvement, and a companion post on professional networks will accompany its release.

The company's presentation is expected to focus on the mechanism of action behind its nanobody platform and the potential applications of that platform across a range of therapeutic areas. The platform is designed to target specific cancer cells and offers characteristics distinct from traditional monoclonal antibodies. PHP Biotech's pipeline includes additional humanized camelid nanobodies under development for TNBC and other cancers.

PHP Biotech is a US-based biotechnology company focused on nanobody and translational biotechnology. The company develops novel therapeutic nanobodies intended to target and destroy cancer cells, with a lead candidate, PHP53-nb, designed to reactivate the functionality of the p53 protein. Its team of healthcare entrepreneurs, scientists, and researchers conducts research and development aimed at addressing aggressive cancers, including triple-negative breast cancer. The company maintains a nanobody platform intended to support a variety of therapeutic applications across its development pipeline.

###

For more information about PHP Biotech, contact the company here:

PHP Biotech
Robert Gahagen
555-555-5555
contact@phpbiotech.com
550 Reserve St. STE 190​
Southlake, TX 76092